12:37 uur 15-05-2019

Knopp Biosciences presenteert gegevens over zijn kaliumkanaalactivatorprogramma in 2019 Antiepileptic Drug and Device Trials XV Conference

Het Kv7-programma van het bedrijf is gericht op het tegengaan van epilepsie en andere neurologische aandoeningen

PITTSBURGH–(BUSINESS WIRE)–Knopp Biosciences LLC, een particulier geneesmiddelontdekkings- en ontwikkelingsbedrijf dat zich richt op het leveren van baanbrekende behandelingen voor inflammatoire en neurologische aandoeningen met een hoge onvervulde behoefte, heeft vandaag aangekondigd dat het bedrijf zijn Kv7-activatorprogramma voor precisiemedicijnen voor de behandeling van KCNQ2-neonatale epileptische encefalopathie (KCNQ2-NEE) zal presenteren op de Antiepileptic Drug and Device Trials XV-conferentie, te houden in Miami, FL van 22 tot 24 mei. KCNQ2-NEE, een zeldzame genetische vorm van epilepsie, is het resultaat van mutaties in genen bij het Kv7.2/Kv7.3-ionkanaal, wat leidt tot frequente aanvallen en abnormale hersenontwikkeling.

Presentatietitel: Targeting van Kv7.2/7.3 Activators voor de behandeling van KCNQ2-NEE

Spreker: Steven Dworetzky, PhD, Chief Scientific Officer, Knopp Biosciences

Datum en tijd: 24 mei 2019, 10:00 uur Eastern Time

Knopp Biosciences to Present Data on Its Potassium Channel Activator Program at 2019 Antiepileptic Drug and Device Trials XV Conference

Company’s Kv7 program targets epilepsy and other neurological conditions

PITTSBURGH–(BUSINESS WIRE)– Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today announced that the company will present its precision medicine Kv7 activator program for the treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference, to be held in Miami, FL on May 22-24. KCNQ2-NEE, a rare genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and abnormal brain development.

Presentation Title: Targeting Kv7.2/7.3 Activators for the Treatment of KCNQ2-NEE

Speaker: Steven Dworetzky, PhD, Chief Scientific Officer, Knopp Biosciences

Date & Time: May 24, 2019, 10:00 am Eastern Time

Ion channels are proteins that regulate the excitability of cells, and drugs that modulate ion channels play an important role in treating a variety of neurological and cardiovascular conditions. Among ion channel targets, potassium channels play a key role in the pathophysiology of epilepsy and other unmet needs in diseases of the nervous system. Knopp is advancing a library of Kv7.2/7.3 channel activators to modulate this key ion channel in nerve cells, targeting a devastating genetic mutation associated with neonatal encephalopathy, as well as other rare epilepsies and neuropathic pain.


Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 3 development in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, and neuropathic pain. Please visit www.knoppbio.com.

Knopp’s Kv7 research is supported under Award Number U44NS093160 of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The content of this announcement is solely the responsibility of Knopp and does not necessarily represent the views of the NIH.

This press release contains “forward-looking statements,” including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp’s actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp’s pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.


Media inquiries:
James Heins

Check out our twitter: @NewsNovumpr